Scipher Medicine
Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis (RA).
Rheumatoid Arthritis
Lab Collection Only
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 1100 participants |
Official Title : | PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT) |
Actual Study Start Date : | 2024-04-08 |
Estimated Primary Completion Date : | 2025-06-30 |
Estimated Study Completion Date : | 2025-12-31 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 100 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Medvin Clinical Research//Amicus Arthritis
Whittier, California, United States, 90602